Sandra M. Gurrola - 21 Jun 2021 Form 3 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Vice President of Finance
Signature: /s/ Mark L. Johnson, Attorney-in-Fact for Sandra M. Gurrola
Issuer symbol: ERNA
Transactions as of: 21 Jun 2021
Net transactions value: $0
Form type: 3
Filing time: 22 Jun 2021, 18:00:20 UTC
Next filing: 17 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ERNA	Common Stock						8,203	21 Jun 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Ms. Gurrola previously served as Senior Vice President of Finance for Brooklyn ImmunoTherapeutics, Inc. (formerly NTN Buzztime, Inc.) (the "Company"). As reported on an exit Form 4 filed with the Securities and Exchange Commission on March 26, 2021, Ms. Gurrola ceased to be a Section 16 Reporting Officer of the Company effective as of March 25, 2021. Effective as of June 21, 2021, Ms. Gurrola was appointed Vice President of Finance of the Company and thereby again became a Section 16 Reporting Officer of the Company. This Form 3 presents a current listing of all holdings of Company securities as of the effective time of Ms. Gurrola's appointment as Vice President of Finance of the Company. Exhibit List: Exhibit 24 - Power of Attorney